Cardiovascular risk following cannabinoid treatment for patients with chronic pain

27 August 2022 (12:15 - 13:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Miss Nina Nouhravesh

Duke Clinical Research Institute, Durham (United States of America)

6 More presentations in this session

Presentation thumbnail

Berberine associated to SGLT2i Dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to Trastuzumab through reduction of AGEs and IL-6 and induction of pAMPK

Doctor N. Maurea (Naples, IT)

Abstract Slides

Presentation thumbnail

Dose-dependency of diclofenac's cardiovascular risks: a series of nationwide emulated trials

Associate Professor M. Schmidt (Aarhus, DK)

Abstract Slides

Presentation thumbnail

Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissue

Doctor N. Maurea (Naples, IT)

Abstract Slides

Presentation thumbnail

Incidence of drug-drug interactions of QT-prolonging drugs in an onco-hematological outpatient

Mr E. Fort (Barcelona, ES)

Abstract Slides

Presentation thumbnail

Sacubitril-valsartan activates pAMPK and reduces NLRP3, MyD88, cytokines/growth factors and DAMPs in doxorubicin-treated mice improving longitudinal strain and ejection fraction

Doctor N. Maurea (Naples, IT)

Abstract Slides

Access the full session

Session thumbnail

Drug cardiotoxicity: what do we need to know?

The Event

Event poster

ESC Congress 2022

27 August 2022 12:15 CET

You may be interested in

Webinar

Multidisciplinary strategies for monitoring and managing cardiovascular toxicity in patients with cancer

Congress Session

Recent perspectives in cardio-oncology

Congress Session

Cardio-oncology: when therapy leads to failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources